Clinical Trials Logo

Clinical Trial Summary

The goal of this research study is to determine whether changes in organ-specific uptake of 124I- AT-01 can be measured by PET/CT imaging and further, whether these values correlate with changes in a subject's disease status and thereby enable monitoring of disease response over time in terms of organ-specific amyloid load.


Clinical Trial Description

This is a single center, open label, prospective study using 124I-AT-01 PET/CT imaging to evaluate changes in amyloid load in patients with systemic amyloidosis who had undergone 124I-AT-01 imaging. Consented eligible patients will provide 3 tablespoons of blood for the following laboratory tests: CMP, CBC, CRP, Troponin, NT-proBNP, LDH, FLC and anti-drug antibody (ADA) analyses. A urine sample will also be collected to assess renal function. If required, a pregnancy test will be administered. Patients will then undergo a transthoracic echocardiographic examination and vital sign assessment before receiving an intravenous injection of no more than 2 mCi 124I-AT-01 followed, 5 h thereafter, by repeat vital sign measurements and PET/CT imaging from crown to thighs with a dynamic PET acquisition over the heart. Previously acquired 124I- AT-01 PET/CT images will be used as baseline values to determine quantitative changes in uptake of the radiotracer in the heart, liver, spleen, and kidney (and other organs deemed positive following visual inspection of the baseline and repeat imaging) as a measure of changes in amyloid load. Optionally, if the patients can return to the study site within ~30 days post injection of 124I-AT-01, a second (post-injection) blood draw and ADA evaluation will be performed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05968846
Study type Interventional
Source University of Tennessee Graduate School of Medicine
Contact
Status Active, not recruiting
Phase Phase 2
Start date December 7, 2022
Completion date June 2024

See also
  Status Clinical Trial Phase
Completed NCT03678259 - 124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis Phase 1/Phase 2
Recruiting NCT06342466 - Bortezomib, Pomalidomide, Dexamethasone For Systemic AL Amyloidosis Phase 2
Recruiting NCT04006223 - The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis
Recruiting NCT05951816 - A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis Phase 1
Recruiting NCT06186167 - Amyloidosis Incidence in High-Risk Cardiac Device Patients
Recruiting NCT05150353 - Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis (AMYLOCARP) N/A